U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H9Cl2N3S2
Molecular Weight 354.277
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of LULICONAZOLE

SMILES

ClC1=CC=C([C@@H]2CS\C(S2)=C(\C#N)N3C=CN=C3)C(Cl)=C1

InChI

InChIKey=YTAOBBFIOAEMLL-REQDGWNSSA-N
InChI=1S/C14H9Cl2N3S2/c15-9-1-2-10(11(16)5-9)13-7-20-14(21-13)12(6-17)19-4-3-18-8-19/h1-5,8,13H,7H2/b14-12+/t13-/m0/s1

HIDE SMILES / InChI

Description

Luliconazole (trade names Luzu, Lulicon) is an imidazole antifungal drug. As a 1% topical cream, It is indicated for the treatment of athlete's foot, jock itch, and ringworm caused by dermatophytes such as Trichophyton rubrum, Microsporum gypseum and Epidermophyton floccosum. Luliconazole is an antifungal that belongs to the azole class. Although the exact mechanism of action against dermatophytes is unknown, luliconazole appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase. Inhibition of this enzyme’s activity by azoles results in decreased amounts of ergosterol, a constituent of fungal cell membranes, and a corresponding accumulation of lanosterol. Pharmacokinetic and safety results from phase 1 studies in patients with onychomycosis have demonstrated high concentrations of luliconazole within the nail plates of the great toe and have shown that this agent is well tolerated when administered as a 10% solution.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
LUZU
Curative
LUZU
Curative
LUZU
Curative
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
0.1 ng/mL
20 mg 1 times / day steady-state, topical
[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE plasma
Homo sapiens
0.93 ng/mL
35 mg 1 times / day steady-state, topical
[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
1.72 ng × h/mL
20 mg 1 times / day steady-state, topical
[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE plasma
Homo sapiens
18.74 ng × h/mL
35 mg 1 times / day steady-state, topical
[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
19.9 h
20 mg 1 times / day steady-state, topical
[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
35 mg 1 times / day steady-state, topical
[NO STEREO] LULICONAZOLE, (+/-)-|[NO STEREO] LULICONAZOLE, (+)-|[NO STEREO] LULICONAZOLE plasma
Homo sapiens

Doses

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
When treating interdigital tinea pedis, a thin layer of LUZU Cream, 1% should be applied to the affected area and approximately 1 inch of the immediate surrounding area(s) once daily for two (2) weeks. When treating tinea cruris or tinea corporis, LUZU Cream, 1% should be applied to the affected area and approximately 1 inch of the immediate surrounding area(s) once daily for one (1) week.
Route of Administration: Topical
In Vitro Use Guide
Luliconazole inhibited growth of all filamentous fungi except zygomycetes at low concentrations (MIC, < or =0.004-0.125 microg/ml), with dermatophytes being most susceptible (MIC, < or =0.004-0.008 microg/ml).